Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2015 2
2016 2
2017 2
2018 2
2019 1
2020 2
2021 4
2022 5
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
The Lancet Breast Cancer Commission.
Coles CE, Earl H, Anderson BO, Barrios CH, Bienz M, Bliss JM, Cameron DA, Cardoso F, Cui W, Francis PA, Jagsi R, Knaul FM, McIntosh SA, Phillips KA, Radbruch L, Thompson MK, André F, Abraham JE, Bhattacharya IS, Franzoi MA, Drewett L, Fulton A, Kazmi F, Inbah Rajah D, Mutebi M, Ng D, Ng S, Olopade OI, Rosa WE, Rubasingham J, Spence D, Stobart H, Vargas Enciso V, Vaz-Luis I, Villarreal-Garza C; Lancet Breast Cancer Commission. Coles CE, et al. Lancet. 2024 Apr 12:S0140-6736(24)00747-5. doi: 10.1016/S0140-6736(24)00747-5. Online ahead of print. Lancet. 2024. PMID: 38636533 Review. No abstract available.
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations.
Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, de Azambuja E, Isacke CM, Harbeck N, Kaidar-Person O, Marangoni E, Offersen BV, Rugo HS, Salvestrini V, Visani L, Morandi A, Lambertini M, Poortmans P, Livi L; Consensus Panellist Group. Meattini I, et al. Lancet Oncol. 2024 Feb;25(2):e73-e83. doi: 10.1016/S1470-2045(23)00534-X. Lancet Oncol. 2024. PMID: 38301705 Review.
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
Ganz PA, Bandos H, Španić T, Friedman S, Müller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Dueñas EM, Armstrong A, Im SA, Song CG, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, t'Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugère C, Friedlander M, Lee KS, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, Scheepers ED, Cameron D, Garber J, Geyer CE, Tutt ANJ. Ganz PA, et al. Among authors: spanic t. J Clin Oncol. 2024 Apr 10;42(11):1288-1300. doi: 10.1200/JCO.23.01214. Epub 2024 Feb 1. J Clin Oncol. 2024. PMID: 38301187 Clinical Trial.
EUSOMA quality indicators for non-metastatic breast cancer: An update.
Rubio IT, Marotti L, Biganzoli L, Aristei C, Athanasiou A, Campbell C, Cardoso F, Cardoso MJ, Coles CE, Eicher M, Harbeck N, Karakatsanis A, Offersen BV, Pijnappel R, Ponti A, Regitnig P, Santini D, Sardanelli F, Spanic T, Varga Z, Vrancken Peeters MJTFD, Wengström Y, Wyld L, Curigliano G. Rubio IT, et al. Among authors: spanic t. Eur J Cancer. 2024 Feb;198:113500. doi: 10.1016/j.ejca.2023.113500. Epub 2023 Dec 26. Eur J Cancer. 2024. PMID: 38199146
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO).
Kaidar-Person O, Meattini I, Boersma LJ, Becherini C, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Rugo HS, Del Mastro L, Gennari A, Isacke CM, Vestmø Maraldo M, Marangoni E, Nader Marta G, Mjaaland I, Salvestrini V, Spanic T, Visani L, Morandi A, Lambertini M, Livi L, Coles CE, Poortmans P, Offersen BV. Kaidar-Person O, et al. Among authors: spanic t. Radiother Oncol. 2023 Dec 19:110060. doi: 10.1016/j.radonc.2023.110060. Online ahead of print. Radiother Oncol. 2023. PMID: 38122852 Free article. Review.
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk, et al. Lancet. 2023 Apr 15;401(10384):1277-1292. doi: 10.1016/S0140-6736(23)00285-4. Lancet. 2023. PMID: 37061269 Free PMC article.
EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.
Schmidt MK, Kelly JE, Brédart A, Cameron DA, de Boniface J, Easton DF, Offersen BV, Poulakaki F, Rubio IT, Sardanelli F, Schmutzler R, Spanic T, Weigelt B, Rutgers EJT. Schmidt MK, et al. Among authors: spanic t. Eur J Cancer. 2023 Mar;181:79-91. doi: 10.1016/j.ejca.2022.11.036. Epub 2022 Dec 13. Eur J Cancer. 2023. PMID: 36641897 Free PMC article. Review.
Towards Better Pharmaceutical Provision in Europe-Who Decides the Future?
Horgan D, Spanic T, Apostolidis K, Curigliano G, Chorostowska-Wynimko J, Dauben HP, Lal JA, Dziadziuszko R, Mayer-Nicolai C, Kozaric M, Jönsson B, Gutierrez-Ibarluzea I, Fandel MH, Lopert R. Horgan D, et al. Among authors: spanic t. Healthcare (Basel). 2022 Aug 22;10(8):1594. doi: 10.3390/healthcare10081594. Healthcare (Basel). 2022. PMID: 36011250 Free PMC article.
Code of practice needed for samples donated by trial participants.
Coleman R, Chan A, Barrios C, Cameron D, Costa L, Dowsett M, Harrison D, Howell A, Lacombe D, MacKenzie M, Martin M, McIntosh S, Morgan A, Piccart M, Spanic T. Coleman R, et al. Among authors: spanic t. Lancet Oncol. 2022 Mar;23(3):e89-e90. doi: 10.1016/S1470-2045(22)00059-6. Lancet Oncol. 2022. PMID: 35240091 No abstract available.
25 results